Larotrectinib Use in A Patient with A Diffuse High-Grade Glioma with NTRK2 Fusion

High-grade gliomas, particularly in the pineal region, present challenges due to their aggressive nature and the lack of established treatment regimens. Molecular profiling allows clinicians to identify mutations that may be actionable to improve progression-free and overall survival. This report presents the case of a 59-year-old male with a high-grade glioma of the pineal region harboring an NTRK2 fusion who was successfully treated with larotrectinib. His tumor has remained stable for over 24 months, and he is tolerating therapy well, with manageable fatigue and no other significant adverse effects. This case confirms the importance of obtaining molecular profiling to enable administration of targeted treatment options which can in turn improve patient outcomes.